The new dual CAR T cell immunotherapy promises to target the HIV reservoir.


More than 35 million individuals around the world are affected by the global HIV epidemic. A regular treatment that can control but not cure HIV infection is antiretroviral therapy (ART). For many people living with HIV, however, access and lifelong adherence to a daily routine is a major obstacle. The viral reservoir, copies of HIV locked away in the genome of infected cells, is a significant obstacle to HIV treatment. If treatment with ART is avoided, the virus is able to produce new copies of itself easily, leading eventually to the development of AIDS. CAR T cells are an effective immunotherapy currently used in cancer therapies, in which Chimeric Antigen Receptors (CARs) are engineered to express the patient's own immune T cells. In order to identify and remove particular diseased or contaminated cells, such as cancer cells or, possibly, HIV infected cells, these CARs re-program the T cells. By detecting viral antigens presented by human leukocyte antigen ( HLA) class I and destroying infected cells, the HIV-specific CD8 + cytotoxic T lymphocyte (CTL) response plays a critical role in limiting virus replication in vivo. However, in the absence of combination antiretroviral therapy (cART), the CTL response fails to durably control HIV replication. We agree that the ability of these protected Dual CAR T cells to minimise the HIV burden in a variety of tissues and cell types, including long-lived CD4 + T memory cells, supports the use of CAR T cell therapy as a new method to target the HIV reservoir for a functional HIV cure. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this